Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 3/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.48 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1014404 | 0.85 | S1PR5 (0.50) | GRIN2BS1PR1S1PR5FUCA1DRD4 | |
| SCHEMBL4188612 | 0.84 | CHRM3 (0.43) | GRIN2BS1PR1S1PR5 | |
| SCHEMBL4190801 | 0.84 | CHRM3 (0.43) | GRIN2BS1PR1S1PR5 | |
| SCHEMBL13875520 | 0.83 | CHRM3 (0.46) | GRIN2B | |
| SCHEMBL4245976 | 0.83 | DRD2 (0.58) | DRD4DRD2 | |
| SCHEMBL4248205 | 0.82 | BACE1 (0.55) | DRD4DRD2KMT2ASIGMAR1 | |
| SCHEMBL4200481 | 0.81 | GRIN2B (0.43) | GRIN2BS1PR1S1PR5 | |
| SCHEMBL4242462 | 0.81 | DRD2 (0.43) | DRD4DRD2DRD3 | |
| SCHEMBL4189388 | 0.81 | GRIN2B (0.43) | GRIN2BS1PR1S1PR5 | |
| SCHEMBL4237299 | 0.81 | CHRNB2 (0.54) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-04-23 | — | — | US | disclosed |
| EP-1797040-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035303-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | GRIN2B 626/4885S1PR1 305/4885S1PR5 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.